Novo Nordisk reported second-quarter revenue of DKK 76.9 billion (about US$11.9 billion), a 13 percent increase that narrowly topped analysts’ expectations but marked the Danish drugmaker’s slowest quarterly growth in four years. Operating profit fell short of consensus at DKK 33.4 billion, and earnings per share slipped below forecasts as heightened competition pressed on margins in the key U.S. obesity-drug market. Sales of Wegovy, the company’s flagship weight-loss injection, jumped 67 percent to DKK 19.5 billion and now account for nearly all of the DKK 20.4 billion generated by Novo Nordisk’s obesity-care division. Wegovy is available in 35 countries, up from about 25 three months earlier, underscoring the firm’s push to offset intensifying rivalry in the United States, where U.S. operations delivered DKK 43.0 billion in revenue during the quarter. For the first six months of 2025, group sales rose 16 percent in Danish kroner, or 18 percent at constant exchange rates, to DKK 154.9 billion. Management left its full-year guidance unchanged after trimming it last week, still projecting 8–14 percent sales growth as it contends with copycat products and new entrants in the glucose-lowering and weight-loss segments.